Coya Therapeutics Inc. (COYA), a clinical-stage biotechnology company, which is optimistic about the strategic opportunities that lie ahead, both with existing and new partners, looks forward to delivering shareholder value in 2025.
The company expects to present additional data from its Phase 2 investigator-initiated study of COYA 302, otherwise known as Low Dose Interleukin-2 (LD IL-2), in patients with mild-to-moderate Alzheimer's next quarter (Q1, 2025).
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.